Medium Chain Triglycerides (MCT Oil)
**Medium Chain Triglycerides (MCTs)** are specialized lipid fractions (primarily caprylic [C8] and capric [C10] saturated fatty acids) derived from coconut oil. They are utilized in veterinary medicine primarily as an easily digestible caloric source for patients with compromised gastrointestinal fat absorption. **Key Clinical Uses:** * **Fat Malabsorption Syndromes:** Used to provide calories to dogs with restricted long-chain fat intake due to conditions like **protein-losing enteropathy (PLE)**, **lymphangiectasia**, **exocrine pancreatic insufficiency (EPI)**, or severe **inflammatory bowel disease (IBD)**. * **Drug Vehicle:** Highly accepted by cats as a base-vehicle for compounding or administering oral medications. *Clinical Pearl:* While MCT oil provides readily available calories, it **does not contain essential fatty acids** (like linoleic acid). Patients on long-term ultra-low-fat diets supplemented only with MCT oil may require separate essential fatty acid supplementation. Today, many clinicians prefer using highly digestible, ultra-low-fat commercial prescription diets over adding MCT oil to homemade diets due to palatability issues.
Mechanism: MCTs bypass the traditional, complex lipid digestion and absorption pathways required by long-chain triglycerides (LCTs): **Triglycerides** → hydrolyzed by **gastric and pancreatic lipases** (requires significantly less bile acids than LCTs) → **Medium-chain fatty acids (MCFAs)** → absorbed directly into enterocytes → enter the **portal vein** directly (bypassing **chylomicron** formation and **lymphatic transport**) → rapid oxidation in the liver for immediate energy. Because they do not rely on the lymphatic system, they are ideal for patients with lymphatic obstruction or dilation (e.g., lymphangiectasia).
Dosing by species
- Base-vehicle to administer drugs · 0.1 mL/kg · PO · as needed · Owner-perceived acceptability by cats of MCT oil was significantly higher than gelatin capsules.
- To offset caloric reduction when long-chain triglycerides are restricted · ½-4 teaspoons divided per day with food · PO · divided daily
- To offset caloric reduction when long-chain triglycerides are restricted · 0.5-2 mL/kg per day added to food · PO · daily
- To offset caloric reduction when long-chain triglycerides are restricted · 1-2 mL/kg per day · PO · daily
Doses are a clinical reference for licensed veterinary professionals. Always confirm against the current label and the individual patient.
Routes of administration
Contraindications
- Significant hepatic disease (e.g., portosystemic shunts, cirrhosis, hepatic failure)
Adverse effects
- Unpalatability (especially in dogs)
- Bloating
- Flatulence
- Diarrhea
- Food aversion (rare in cats)
Drug interactions
- Griseofulvin · MCT oil may decrease absorption, as griseofulvin requires long-chain dietary fats for optimal oral absorption.
- Fat-soluble vitamins (A, D, E, K) · Absorption may be impaired if LCTs are completely replaced by MCTs; supplementation may be required.
Monitoring
- Gastrointestinal tolerance (vomiting, bloating, flatulence, stool consistency)
- Efficacy (maintenance of body weight and body condition score)
- Signs of hepatic encephalopathy in patients with underlying liver disease
Overdose
Overdosage primarily exacerbates gastrointestinal adverse effects, leading to **bloating, flatulence, and severe diarrhea**. **Treatment:** * Discontinue or reduce the dose of MCT oil. * Treat severe diarrhea supportively (e.g., fluid therapy to correct dehydration and electrolyte imbalances) if necessary.
VetSheet drug reference is intended for licensed veterinary professionals as a clinical decision-support aid, not a substitute for professional judgement or the manufacturer’s current label.